If you have been reading about peptide mapping and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-10. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
In 2011, tourists visiting Ghana numbered 1,087,000, with arrivals including South Americans, Asians, Europeans, and North Americans. Among the attractions and tourist destinations are waterfalls such as Kintampo waterfalls and the largest waterfall in west Africa, Wli waterfalls, the coastal palm-lined sandy beaches, caves, mountains, rivers, and reservoirs and lakes such as Lake Bosumtwi and the largest human-made lake in the world by surface area, Lake Volta, dozens of forts and castles, World Heritage Sites, nature reserves and national parks. Castles include Cape Coast Castle and the Elmina Castle. Castles mark where blood was shed in the slave trade and preserve and promote the African heritage stolen and destroyed through the slave trade. The World Heritage Convention of UNESCO named Ghana's castles and forts as World Heritage Monuments: "The Castles and Forts of Ghana shaped not only Ghana's history but that of the world over four centuries as the focus of first the gold trade and then the slave trade. They are a significant and emotive symbol of European–African encounters and of the starting point of the African Diaspora." The World Economic Forum statistics in 2010 showed that out of the world's favourite tourist destinations, Ghana was ranked 108th out of 139 countries. The country had moved two places up from the 2009 rankings. In 2011, Forbes magazine published that Ghana was ranked the 11th most friendly country in the world. The assertion was based on a survey in 2010 of a cross-section of travellers.
== Growth and morphology == The filamentous non-soil associated fungus does not require any specific growth condition in culture. E. floccosum does not grow on urease culture, has low osmotolerance, and is unable to form perforating organs. The colonies have khaki suede-like flat surfaces and grow moderately rapidly, reaching maturity within 10 days. The reverse is reddish-brown. Colonies are initially flat, but the centre of which later becomes raised and folded, with the periphery submerged. On rich media like Sabouraud agar, colonies usually degenerate into white pleomorphic tufts within several weeks, and sometimes exude a red-brown pigment into its agar. E. floccosum has septate, hyaline hyphae. Its key features are the smooth, thin-walled, club-shaped macroconidia and the absence of microconidia. The macroconidia are borne singly or in clusters of 2 or 3; they are 20–40 μm in length and 7–12 μm in width, consisting of 1 to 9 septa. The narrow base and broad, club-shaped apex of the macroconidium have been compared in shape to a beaver tail. The fungus reproduces asexually through chlamydoconidia, which are resting spores that are abundant in culture. Arthroconidia are also abundant in the culture, emerging as swollen cells alongside macroconidia formation; these thick-walled spores are resistant to heat and drying conditions.
Mass spectrometry imaging (MSI) is a technique used in mass spectrometry to visualize the spatial distribution of molecules, as biomarkers, metabolites, peptides or proteins by their molecular masses. After collecting a mass spectrum at one spot, the sample is moved to reach another region, and so on, until the entire sample is scanned. By choosing a peak in the resulting spectra that corresponds to the compound of interest, the MS data is used to map its distribution across the sample. This results in pictures of the spatially resolved distribution of a compound pixel by pixel. Each data set contains a veritable gallery of pictures because any peak in each spectrum can be spatially mapped. Despite the fact that MSI has been generally considered a qualitative method, the signal generated by this technique is proportional to the relative abundance of the analyte. Therefore, quantification is possible, when its challenges are overcome. Although widely used traditional methodologies like radiochemistry and immunohistochemistry achieve the same goal as MSI, they are limited in their abilities to analyze multiple samples at once, and can prove to be lacking if researchers do not have prior knowledge of the samples being studied. Most common ionization technologies in the field of MSI are DESI imaging, MALDI imaging, secondary ion mass spectrometry imaging (SIMS imaging) and Nanoscale SIMS (NanoSIMS).
Sources: en.wikipedia.org
==== Conjugated ==== In the liver, bilirubin is conjugated with glucuronic acid by the enzyme glucuronyltransferase, first to bilirubin glucuronide and then to bilirubin diglucuronide, making it soluble in water: the conjugated version is the main form of bilirubin present in the "direct" bilirubin fraction. Much of it goes into the bile and thus out into the small intestine. Though most bile acid is reabsorbed in the terminal ileum to participate in enterohepatic circulation, conjugated bilirubin is not absorbed and instead passes into the colon. There, colonic bacteria deconjugate and metabolize the bilirubin into colorless urobilinogen, which can be oxidized to form urobilin and stercobilin. Urobilin is excreted by the kidneys to give urine its yellow color and stercobilin is excreted in the feces giving stool its characteristic brown color. A trace (~1%) of the urobilinogen is reabsorbed into the enterohepatic circulation to be re-excreted in the bile. Conjugated bilirubin's half-life is shorter than delta bilirubin.
Amino acid N-carboxyanhydrides, also called Leuchs' anhydrides, are a family of heterocyclic organic compounds derived from amino acids. They are white, moisture-reactive solids. They have been evaluated for applications the field of biomaterials.
Multiple epiphyseal dysplasia (MED), also known as Fairbank's disease, is a rare genetic disorder (dominant form: 1 in 10,000 births) that affects the growing ends of bones. Long bones normally elongate by expansion of cartilage in the growth plate (epiphyseal plate) near their ends. As it expands outward from the growth plate, the cartilage mineralizes and hardens to become bone (ossification). In MED, this process is defective.
== Epidemiology == According to a Japanese study from 2007, Bethlem myopathy 1 affects about 1 in 200,000 people. A 2009 study, concerning the prevalence of genetic muscle disease in Northern England, estimated the prevalence of Bethlem myopathy 1 to be at 0.77:100,000. Together with Ullrich congenital muscular dystrophy 1, Bethlem myopathy 1 is believed to be underdiagnosed. Both conditions have been described in individuals from a variety of ethnic backgrounds. Bethlem myopathy 2 affects less than 1 in 1,000,000 people.
Sources: en.wikipedia.org
Fast breeder reactors (FBRs) which use 'fast' (i.e. unmoderated) neutrons to breed fissile plutonium (and possibly higher transuranics) from fertile uranium-238. The fast spectrum is flexible enough that it can also breed fissile uranium-233 from thorium, if desired. Thermal breeder reactors which use 'thermal-spectrum' or 'slow' (i.e. moderated) neutrons to breed fissile uranium-233 from thorium. Due to the behavior of the various nuclear fuels, a thermal breeder is thought commercially feasible only with thorium fuel, which avoids the buildup of the heavier transuranics.
== Medical uses == Secukinumab is used to treat psoriasis, ankylosing spondylitis, psoriatic arthritis, and hidradenitis suppurativa. It is given by subcutaneous injection and is sold in a pre-filled syringe or autoinjector that can be used at home and as a lyophilized powder for use in hospitals and clinics. In October 2023, the FDA approved an intravenous variant of secukinumab. Secukinumab was not tested in pregnant women; animal studies did not show harm at relevant doses. The US Food and Drug Administration advises that the drug should be used in pregnant women only if the risk to the fetus is justified by the potential benefit; the European Medicines Agency (EMA) advises that women should not become pregnant while taking it. In the European Union, secukinumab is indicated for the treatment of:
=== Molecular representations for chirality === Computational methods for representing molecular chirality must encode three-dimensional stereochemical information in a format suitable for machine learning algorithms. SMILES (Simplified Molecular Input Line Entry System) notation incorporates stereochemistry through the use of @ and @@ symbols at chiral centers, where @ typically denotes anticlockwise and @@ denotes clockwise configuration when viewing the chiral center along the bond from the center to the first atom in the SMILES string. Traditional molecular descriptors used in computational chemistry, such as circular fingerprints (Extended Connectivity Fingerprints or ECFP), can encode structural information including stereochemical features. These descriptors represent molecules as fixed-length binary vectors that capture local atomic environments and connectivity patterns. However, conventional fingerprints may not optimally capture the subtle three-dimensional differences between enantiomers. Neural network-based molecular representations can be derived from SMILES strings. Variational autoencoders and heteroencoders trained on large databases of molecular structures can generate latent space vectors (LSVs) that encode molecular properties in a continuous, lower-dimensional space. These methods calculate difference vectors between the descriptor of a molecule and that of its enantiomer, or between the original descriptor and one derived from a stereochemistry-depleted SMILES string.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.